Morgan Stanley Initiates Coverage On Immix Biopharma with Overweight Rating, Announces Price Target of $20

Morgan Stanley analyst Judah Frommer has initiated coverage on Immix Biopharma (NASDAQ: IMMX) with an Overweight rating. The firm has set a price target of $20 for the company's stock.